hydroxychloroquine has been researched along with Cytokine Release Syndrome in 35 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacological treatment of cachexia consists mainly of progestagens and glucocorticosteroids." | 5.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| " Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury." | 5.12 | [Pharmacovigilance update]. ( Ekobena, P; Ivanyuk, A; Livio, F, 2021) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "Favipiravir has resulted in a higher viral clearance than remdesivir." | 2.72 | A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. ( Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| " Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders." | 2.66 | Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. ( Khuroo, MS, 2020) |
| "Pharmacological treatment of cachexia consists mainly of progestagens and glucocorticosteroids." | 1.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| "The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release." | 1.56 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. ( Dai, SM; Tong, Q; Zhou, D, 2020) |
| "Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China." | 1.56 | Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. ( Bhatt, PJ; Narayanan, N; Radbel, J, 2020) |
| "Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7." | 1.56 | Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. ( Baettig, V; Bassetti, S; Battegay, M; Egli, A; Franzeck, F; Gebhard, CE; Geenen, J; Hirsch, HH; Hollinger, A; Khanna, N; Marzolini, C; Mueller, D; Osthoff, M; Sendi, P; Stader, F; Stoeckle, M; Tschudin-Sutter, S; Weisser, M, 2020) |
| "Methemoglobinemia is a rare disorder of the blood in which there is an increase in methemoglobin, which occurs when hemoglobin is present in the oxidized form." | 1.56 | Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report. ( Bloom, A; Faisal, H; Gaber, AO, 2020) |
| "Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic." | 1.56 | Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. ( Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L, 2020) |
| "Sepsis is an overwhelming systemic inflammatory response for which no satisfactory therapeutic drug is available." | 1.51 | Inhibition of autophagy protects against sepsis by concurrently attenuating the cytokine storm and vascular leakage. ( Chao, CH; Lu, LH; Yeh, TM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (2.86) | 24.3611 |
| 2020's | 34 (97.14) | 2.80 |
| Authors | Studies |
|---|---|
| Mendoza-Pinto, C | 1 |
| García-Carrasco, M | 1 |
| Munguía Realpozo, P | 1 |
| Méndez-Martínez, S | 1 |
| Ahmad, B | 1 |
| Ul Hassan, N | 1 |
| Sehar, B | 1 |
| Zeb, F | 1 |
| E Nayab, D | 1 |
| Siddiqui, FA | 1 |
| Zhou, D | 1 |
| Dai, SM | 1 |
| Tong, Q | 1 |
| Licciardi, F | 1 |
| Giani, T | 1 |
| Baldini, L | 1 |
| Favalli, EG | 1 |
| Caporali, R | 1 |
| Cimaz, R | 1 |
| Askanase, AD | 1 |
| Khalili, L | 1 |
| Buyon, JP | 1 |
| Radbel, J | 1 |
| Narayanan, N | 1 |
| Bhatt, PJ | 1 |
| Kang, Y | 1 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Lucchino, B | 1 |
| Di Franco, M | 1 |
| Conti, F | 1 |
| Kronbichler, A | 1 |
| Effenberger, M | 1 |
| Eisenhut, M | 1 |
| Lee, KH | 1 |
| Shin, JI | 1 |
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 1 |
| Masoumi, A | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Wu, J | 1 |
| Jacquet-Lagrèze, M | 1 |
| Riad, Z | 1 |
| Hugon-Vallet, E | 1 |
| Ferraris, A | 1 |
| Fellahi, JL | 1 |
| Magro, G | 1 |
| Iannaccone, G | 1 |
| Scacciavillani, R | 1 |
| Del Buono, MG | 1 |
| Camilli, M | 1 |
| Ronco, C | 1 |
| Lavie, CJ | 1 |
| Abbate, A | 1 |
| Crea, F | 1 |
| Massetti, M | 1 |
| Aspromonte, N | 1 |
| Oscanoa, TJ | 1 |
| Romero-Ortuno, R | 1 |
| Carvajal, A | 1 |
| Savarino, A | 1 |
| Marzolini, C | 1 |
| Stader, F | 1 |
| Stoeckle, M | 1 |
| Franzeck, F | 1 |
| Egli, A | 1 |
| Bassetti, S | 1 |
| Hollinger, A | 1 |
| Osthoff, M | 1 |
| Weisser, M | 1 |
| Gebhard, CE | 1 |
| Baettig, V | 1 |
| Geenen, J | 1 |
| Khanna, N | 1 |
| Tschudin-Sutter, S | 1 |
| Mueller, D | 1 |
| Hirsch, HH | 1 |
| Battegay, M | 1 |
| Sendi, P | 1 |
| Khuroo, MS | 1 |
| Ibrahim, H | 1 |
| Perl, A | 1 |
| Smith, D | 1 |
| Lewis, T | 1 |
| Kon, Z | 1 |
| Goldenberg, R | 1 |
| Yarta, K | 1 |
| Staniloae, C | 1 |
| Williams, M | 1 |
| Shamim, S | 1 |
| Khan, M | 1 |
| Kharaba, ZJ | 1 |
| Ijaz, M | 1 |
| Murtaza, G | 1 |
| Burrage, DR | 1 |
| Koushesh, S | 1 |
| Sofat, N | 1 |
| Faisal, H | 1 |
| Bloom, A | 1 |
| Gaber, AO | 1 |
| Caron, P | 1 |
| Gao, C | 1 |
| Zhu, L | 1 |
| Jin, CC | 1 |
| Tong, YX | 1 |
| Xiao, AT | 1 |
| Zhang, S | 1 |
| Pimentel, J | 1 |
| Andersson, N | 1 |
| Fatima, U | 1 |
| Rizvi, SSA | 1 |
| Raina, N | 1 |
| Fatima, S | 1 |
| Rahman, S | 1 |
| Kamal, MA | 1 |
| Hassan, MI | 1 |
| Kiedrowski, M | 1 |
| Kapala, P | 1 |
| Kiedrowska, M | 1 |
| Skoczynska, A | 1 |
| Czerw, A | 1 |
| Deptała, A | 1 |
| Bahadoram, M | 1 |
| Keikhaei, B | 1 |
| Saeedi-Boroujeni, A | 1 |
| Mahmoudian-Sani, MR | 1 |
| Ekobena, P | 1 |
| Ivanyuk, A | 1 |
| Livio, F | 1 |
| Kheirabadi, D | 1 |
| Haddad, F | 1 |
| Mousavi-Roknabadi, RS | 1 |
| Rezaeisadrabadi, M | 1 |
| Dehghan, H | 1 |
| Fazlzadeh, A | 1 |
| Blaess, M | 1 |
| Kaiser, L | 1 |
| Sommerfeld, O | 1 |
| Csuk, R | 1 |
| Deigner, HP | 1 |
| Tascioglu, D | 1 |
| Akkaya, E | 1 |
| Genc, S | 1 |
| Corominas, H | 1 |
| Castellví, I | 1 |
| Diaz-Torné, C | 1 |
| Matas, L | 1 |
| de la Rosa, D | 1 |
| Mangues, MA | 1 |
| Moya, P | 1 |
| Pomar, V | 1 |
| Benito, N | 1 |
| Moga, E | 1 |
| Sosa, NH | 1 |
| Casademont, J | 1 |
| Domingo, P | 1 |
| Lu, LH | 1 |
| Chao, CH | 1 |
| Yeh, TM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh[NCT04434144] | 116 participants (Actual) | Observational [Patient Registry] | 2020-05-02 | Completed | |||
| An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults[NCT05808231] | 100 participants (Anticipated) | Interventional | 2021-04-26 | Recruiting | |||
| Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)[NCT04627467] | Phase 2 | 3,217 participants (Actual) | Interventional | 2020-03-28 | Completed | ||
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19[NCT04560205] | Phase 1 | 50 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer[NCT04659200] | 20 participants (Actual) | Observational | 2020-09-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
21 reviews available for hydroxychloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined | 2021 |
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.
Topics: Anti-Bacterial Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; | 2020 |
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
Tackle the free radicals damage in COVID-19.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Azithromycin; Betacoronavirus; Clinical Trials | 2020 |
Left ventricular dysfunction in COVID-19: A diagnostic issue.
Topics: Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytokine Release Syndro | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mono | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis | 2020 |
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autopha | 2020 |
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
Immunomodulatory Drugs in the Management of SARS-CoV-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Colchi | 2020 |
Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
Topics: Angiotensin-Converting Enzyme 2; Apoptosis; Betacoronavirus; Coronavirus Infections; COVID-19; COVID | 2020 |
Chloroquine and its derivatives in the management of COVID-19: A scoping review
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials; | 2020 |
Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations.
Topics: Antiviral Agents; COVID-19; COVID-19 Serotherapy; Cytokine Release Syndrome; Humans; Hydroxychloroqu | 2021 |
Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
Topics: Anti-Inflammatory Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; H | 2021 |
[Pharmacovigilance update].
Topics: Adenosine Monophosphate; Alanine; Cleft Lip; Contraindications, Drug; COVID-19 Drug Treatment; Cytok | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre | 2021 |
The understanding of the immunopathology in COVID-19 infection.
Topics: Adrenal Cortex Hormones; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Rele | 2021 |
1 trial available for hydroxychloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Hy | 2021 |
13 other studies available for hydroxychloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrom | 2020 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co | 2020 |
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Azi | 2020 |
COVID-19: an unexpected indication for anti-rheumatic therapies?
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Ch | 2020 |
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus | 2020 |
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
Topics: Acetylcysteine; Adult; Antioxidants; Antirheumatic Agents; Betacoronavirus; Biomarkers; C-Reactive P | 2020 |
Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report.
Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Humanized; Antioxidants; Ascorbic Acid; Betacoron | 2020 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug | 2020 |
Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19.
Topics: Autophagy; Cachexia; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Hum | 2021 |
Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Topics: Antiviral Agents; Chlorpromazine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug | 2021 |
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
Topics: Aged; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Azithromycin; Comorbidity; COVID-19; | 2021 |
Inhibition of autophagy protects against sepsis by concurrently attenuating the cytokine storm and vascular leakage.
Topics: Animals; Autophagy; Capillary Permeability; Cytokine Release Syndrome; Cytokines; Endothelium, Vascu | 2019 |